https://www.biohealthcapital.com Advancing Science. Accelerating Innovation. Fri, 13 Sep 2024 18:14:06 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.15 https://www.biohealthcapital.com/news/women-building-bio-xx-factor-2017/ http://www.biohealthcapital.com/?p=1568 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:52:18 +0000 Women Building Bio: the XX factor is a day long conference to recognize and learn from leading women in the bioscience industry as pioneers paving the path to success. These women have faced their own unique challenges and carved out lasting legacies. This day will catalyze the formation of a diverse network. It is a convergence of academia and industry, men and women, researchers and innovators, professionals and decision-makers gathering together to build relationships. This day long conference provides extraordinary opportunities to exchange new ideas, highlight areas of bioscience and research opportunities, and find partners for future collaboration.]]> https://www.biohealthcapital.com/news/7th-annual-tedcos-entrepreneur-expo/ http://www.biohealthcapital.com/?p=1564 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:47:39 +0000 TEDCO’s 7th Annual Entrepreneur Expo will bring together all of Maryland’s entrepreneurial resources from across the state into one place, at one time. You can expect to see 700+ of the region’s top entrepreneurs, small and large business executives, angel and venture capital investors, federal and state economic development officials, university leaders and legislators.]]> https://www.biohealthcapital.com/news/emergent-biosolutions-buy-gsks-anthrax-treatment-raxibacumab-2/ http://www.biohealthcapital.com/?p=1562 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:44:10 +0000 Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m. Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.]]> https://www.biohealthcapital.com/news/um-ventures-helped-biotech-startup-get-acquired-18-months/ http://www.biohealthcapital.com/?p=1559 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:42:07 +0000 A startup that spun out of research at the University of Maryland School of Medicine was acquired 18 months after forming.]]> https://www.biohealthcapital.com/news/emmes-corporation-wins-70-million-contract-pediatric-research/ http://www.biohealthcapital.com/?p=1556 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:38:40 +0000 ROCKVILLE, Md., Aug. 2, 2017 /PRNewswire-USNewswire/ -- The Emmes Corporation today announced that it was awarded a contract from the National Institutes of Health to support pediatric clinical trials sponsored by the National Institute of Child Health and Human Development (NICHD). Valued at nearly $70 million, the 10-1/2 year contract will support the NIH's effort to improve the labeling of drugs for pediatric use.]]> https://www.biohealthcapital.com/news/brainscope-completes-16-million-equity-fundraise/ http://www.biohealthcapital.com/?p=1553 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:30:59 +0000 BETHESDA, MD. August 30, 2017 – BrainScope Company, Inc., the medical neurotechnology company which created the first FDA-cleared handheld medical device for assessment of the full spectrum of traumatic brain injury, today announced it has completed a $16 million equity financing. New investor DBL Partners joined previous backers Revolution LLC, ZG Ventures, Maryland Venture Fund and other existing and new investors in the round, which the company will use to support the commercial launch of its flagship BrainScope One medical device, as well as for continued research and development initiatives. ]]> https://www.biohealthcapital.com/news/maryland-biotech-expanding-new-gaithersburg-headquarters/ http://www.biohealthcapital.com/?p=1550 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:23:55 +0000 Gaithersburg-based immunotherapy company Altimmune Inc. announced Tuesday it plans to expand into a new headquarters, but it's not going far.]]> https://www.biohealthcapital.com/news/washington-not-silicon-valley-leads-way-cybersecurity-nextgov-com/ http://www.biohealthcapital.com/?p=1547 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:20:24 +0000 It’s a common trope that government has a lot to learn from Silicon Valley when it comes to technology. But in cybersecurity, Washington is leading the way in many respects.]]> https://www.biohealthcapital.com/news/1545/ http://www.biohealthcapital.com/?p=1545 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 16:01:50 +0000 MOCONNECT recently interviewed GSK’s Christopher Maddox, Director of Site Operations for The Slaoui Center for Vaccines Research in Rockville. The company made news when it selected Rockville to serve as its U.S. R&D Center, furthering strengthening Montgomery County as a major player in global healthcare.]]> https://www.biohealthcapital.com/news/1541/ http://www.biohealthcapital.com/?p=1541 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 15:15:35 +0000 REGENXBIO Inc. (Nasdaq:RGNX) and Dimension Therapeutics, Inc. (Nasdaq:DMTX) today announced that they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction for an implied value of approximately $3.41 per share. The boards of directors of both companies have unanimously approved the transaction.]]> https://www.biohealthcapital.com/news/biohealth-capital-region-rises-5-gens-annual-rankings-biopharma-clusters/ http://www.biohealthcapital.com/?p=1539 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 08 Sep 2017 15:08:43 +0000 Bruce Booth, D.Phil., a partner at Atlas Venture, astutely observed earlier this year that two key resources fueling the growth of biopharma were until recently somewhat geographically spread among the 10 or so regions of the nation where the industry began to arise a generation ago.]]> https://www.biohealthcapital.com/news/emergent-biosolutions-buy-gsks-anthrax-treatment-raxibacumab/ http://www.biohealthcapital.com/?p=1513 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Jul 2017 14:41:39 +0000 Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m. Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.]]> https://www.biohealthcapital.com/news/nea-makes-history-3-3b-fund/ http://www.biohealthcapital.com/?p=1508 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Mon, 24 Jul 2017 12:54:57 +0000 New Enterprise Associates has closed its 16th flagship fund on $3.3 billion, per the Wall Street Journal, the largest venture vehicle ever raised.]]> https://www.biohealthcapital.com/news/glycomimetics-announces-closing-public-offering-full-exercise-underwriters-option-purchase-additional-shares/ http://www.biohealthcapital.com/?p=1505 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Sun, 23 Jul 2017 12:47:24 +0000 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $92.6 million.]]> https://www.biohealthcapital.com/news/board-visitors-approves-academic-affiliation-inova/ http://www.biohealthcapital.com/?p=1489 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 21 Jul 2017 13:38:53 +0000 The University of Virginia’s Board of Visitors on Friday approved an academic affiliation with the Inova Health System Foundation that includes a research institute and a UVA School of Medicine regional campus.]]> https://www.biohealthcapital.com/news/cybersecurity-blockchain-autonomous-research-take-spotlight-new-virginia-technology-funding/ http://www.biohealthcapital.com/?p=1491 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 13 Jun 2017 13:11:27 +0000 The governor's office announces new awards dedicated to bolstering technology research and commercialization around several emerging markets.]]> https://www.biohealthcapital.com/news/bahija-jallal-medimmune-named-2017-woman-year-healthcare-businesswomens-association/ http://www.biohealthcapital.com/?p=1473 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 23 May 2017 13:01:30 +0000 The Healthcare Businesswomen’s Association (HBA) announced that its 2017 Woman of the Year is Bahija Jallal, PhD, executive vice president, AstraZeneca, and head of MedImmune. MedImmune is the global biologics research and development arm of AstraZeneca.]]> https://www.biohealthcapital.com/news/two-va-research-powerhouses-come-together-projects-seed-fund/ http://www.biohealthcapital.com/?p=1476 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 23 May 2017 08:05:27 +0000 Inova Health System and University of Virginia are kicking off their new partnership with $450,000 in seed money to fund nine joint research projects geared toward better predicting, preventing and treating disease.]]> https://www.biohealthcapital.com/news/long-shot-region-wants-become-top-three-biotech-market-2023/ http://www.biohealthcapital.com/?p=1478 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Sun, 21 May 2017 13:54:32 +0000 Business leaders hope to elevate Greater Washington to top three biotech clusters in U.S. Yeah, good luck.]]> https://www.biohealthcapital.com/news/advancing-science-accelerating-innovation-biohealth-capital-region/ http://www.biohealthcapital.com/?p=1467 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Thu, 11 May 2017 13:50:41 +0000 Collaboration across academia, government, non-profits, and the biopharmaceutical industry fosters innovation and groundbreaking discoveries in science and research. During the 2017 BioHealth Capital Region (BHCR) Forum held at our Gaithersburg, Maryland campus, world-renowned speakers and local leaders convened to showcase the benefits of continued collaboration that can help us prevent, treat, and find cures for deadly diseases.]]> https://www.biohealthcapital.com/news/emergent-biosolutions-opens-expanded-east-baltimore-vaccine-plant/ http://www.biohealthcapital.com/?p=1464 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Mon, 08 May 2017 15:22:46 +0000 When the next flu pandemic strikes or, perish the thought, the Ebola virus starts spreading in the United States, a newly expanded pharmaceutical plant in East Baltimore stands ready to respond.]]> https://www.biohealthcapital.com/news/gsk-invests-139-million-expand-production-capacity-benlysta-belimumab-rockville-md/ http://www.biohealthcapital.com/?p=1461 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Wed, 03 May 2017 14:08:20 +0000 ROCKVILLE, Md., May 1, 2017 /PRNewswire/ -- GSK today announced $139 million of new investment in its biopharmaceutical manufacturing site in Rockville, MD to support growing demand for BENLYSTA® (belimumab) for adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.]]> https://www.biohealthcapital.com/news/hundreds-attend-biohealth-capital-region-forum-gaithersburg/ http://www.biohealthcapital.com/?p=1446 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Apr 2017 14:18:19 +0000 Local business leaders, elected officials, scientists and scholars attended the 2017 BioHealth Capital Region Forum at the campus of MedImmune in Gaithersburg on April 19 and 20th. The forum focuses on the biotechnology cluster in Maryland, Virginia, and Washington, D.C., which is working collaboratively to become a top three biotech hub in the United States by 2023.]]> https://www.biohealthcapital.com/news/biohealth-acceleration-initiative-2/ http://www.biohealthcapital.com/?p=1443 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Apr 2017 14:09:41 +0000 The Maryland Life Sciences Advisory Board (LSAB) was created by the legislature in 2007 to assist in maintaining Maryland’s preeminence in the life sciences industry. Comprised of 18 members, the Board includes the Secretary of the Maryland Department of Commerce, a representative designated by the Maryland Technology Development Corporation (TEDCO), and 16 members appointed by the Governor.]]> https://www.biohealthcapital.com/news/senator-van-hollen-speaks-biohealth-forum/ http://www.biohealthcapital.com/?p=1440 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Apr 2017 14:06:35 +0000 GAITHERSBURG, Md. - The Biohealth Capital Region Forum continued Thursday in Gaithersburg where guests heard from Senator Chris Van Hollen. One of the topics of the forum was funding for the biotech industry. Many national health companies are headquartered in Montgomery County and are concerned about federal funding. President Trump's proposed budget would cut six billion dollars from the National Institute of Health. ]]> https://www.biohealthcapital.com/news/gov-larry-hogan-marylands-life-sciences-cluster-mission-personal-one/ http://www.biohealthcapital.com/?p=1437 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Apr 2017 13:46:53 +0000 When Maryland Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn’t help but take the moment to remember his own brush with their work.]]> https://www.biohealthcapital.com/news/group-launching-website-brand-region-biotech-leader/ http://www.biohealthcapital.com/?p=1434 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Apr 2017 13:43:10 +0000 Greater Washington is so much more than a political “swamp.” But that's the label a group of life science companies and nonprofits — led by Gaithersburg-based MedImmune — said Wednesday they are still fighting against as they try to sell the year-old BioHealth Capital Region brand.]]> https://www.biohealthcapital.com/news/lifesprout-wins-biohealth-capital-region-2nd-annual-crab-trap-competition/ http://www.biohealthcapital.com/?p=1430 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 25 Apr 2017 13:28:06 +0000 ROCKVILLE, MARYLAND, April 24, 2017 –Out of five startup companies selected to present in front of a panel of industry leaders at the 2017 BioHealth Capital Region Forum, LifeSprout was chosen to have the most commercial potential at the 2nd Annual Crab Trap Competition.]]> https://www.biohealthcapital.com/reports/biohealth-acceleration-initiative/ http://www.biohealthcapital.com/?p=1424 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Fri, 21 Apr 2017 13:25:03 +0000 https://www.biohealthcapital.com/news/emergent-biosolutions-signs-53-million-modification-barda-contract-manufacture-botulism-antitoxin/ http://www.biohealthcapital.com/?p=1318 it@biohealthinnovation.org (BHI Admin) https://www.biohealthcapital.com/wp-content/uploads/2017/09/women-building-bio-logo_e8821b704209afdaa4154716b2f72d37.png"/> Tue, 04 Apr 2017 16:25:11 +0000 Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin GAITHERSBURG, Md., March 31, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that...]]>